Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
PROPOFOL
Hospira Enterprises B.V.
10
Emulsion for Inj/Inf
2005-07-01
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Propofol 10mg/ml emulsion for injection or infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml Emulsion for injection or infusion contains 10 mg Propofol. Excipient: 1 ml Emulsion for injection or infusion contains 100 mg Soya-bean oil. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Emulsion for injection or infusion. White to slight off-white emulsion for injection or infusion. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Propofol 10 mg/ml is a short acting intravenous general anaesthetic for: Induction and maintenance of general anaesthesia. Sedation of ventilated patients in the intensive care unit. Sedation for diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Supplemental analgesic agents are normally needed during Propofol administration. In addition, please refer to Section 4.4 Special Warnings and Special Precautions for Use, for additional usage information. _General Anaesthesia in Adults_ Induction: Propofol 10 mg/ml may be used for induction of anaesthesia as slow bolus injection or infusion. Propofol should be titrated to clinical response, where the patient shows sign of anaesthesia (usually about 20-40 mg every 10 seconds). Most adults under 55 years of age will need 1.5 to 2.5 mg/kg. Elderly patients usually need lower doses. Patients in ASA class 3 and 4, especially those with impaired cardiac function, the dosage requirements will be less and the total dose may be reduced to a minimum of 1 mg of propofol/kg body. The total dose could be reduced with a slower administration rate (20 to 50 mg/min). Maintenance: The anaesthesia may be maintained by administration Read the complete document